NDC product
Mucus Relief Extended Release
NDC 11673-732 · TARGET Corporation
Key facts
| Product NDC | 11673-732 |
|---|---|
| Proprietary name | Mucus Relief Extended Release |
| Nonproprietary name | Guaifenesin |
| Substances | GUAIFENESIN |
| Dosage form | TABLET |
| Route | ORAL |
| Labeler | TARGET Corporation |
| Product type | HUMAN OTC DRUG |
| Marketing category | ANDA |
| Application number | ANDA207342 |
| Pharmacologic classes | Decreased Respiratory Secretion Viscosity [PE], Expectorant [EPC], Increased Respiratory Secretions [PE] |
| Marketing start | Jul 11, 2018 |
| Marketing end | Oct 28, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory